SKB571 — Investigational Agent
Antibody-Drug Conjugate · Phase 2 · Sichuan Kelun-Biotech
Mechanism of Action
An antibody-drug conjugate directed at a receptor tyrosine kinase target and carrying a cytotoxic payload, designed to treat MET-abnormal and other solid tumors with targeted delivery and bystander effect.
Investigational Indications
- MET-altered non-small cell lung cancer
- Head and neck squamous cell carcinoma
- Gastrointestinal tumors